Motif A Step Closer To Succeeding With Iclaprim After Phase III Success
Executive Summary
Biotech firm hopes its once-shelved antibiotic will provide a therapeutic option for renally impaired patients with serious skin infections. With only one previous DHFR inhibitor ever approved, Motif also anticipates that iclaprim will offer an option for multidrug-resistant infections.
You may also be interested in...
Money Too Tight To Mention At Motif After Iclaprim 'No' From FDA
Hit with a complete response letter from the US FDA for its antibiotic to treat ABSSSI, Motif needs to raise funds and fast to stay afloat and prepare a meeting package to discuss the next steps for iclaprim with the agency.
Keeping Track: Rebuff Of Iclaprim Creates Early Pileup Of CRLs For Novel Drugs
The latest drug development news and highlights from our US FDA Performance Tracker.
Motif Bio Poised For Filings As Iclaprim Succeeds Again In Phase III
Positive data from a second Phase III trial sets up Motif Bio for an NDA filing by the end of the year for novel antibiotic iclaprim – but success for the product has been a long time coming.